Accreditation Information


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Anticoagulation Forum. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Accreditation

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CNE Contact Hours: 1.00 (final pharmacology credits to be determined)

Continuing Pharmacy Education Credits

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendance and completion of program evaluations at the conclusion of the program are required for a statement of credit. This knowledge-based activity is currently under review for 1.0 Contact Hours (0.1 CEUs).




Needs Statement


With anticoagulation, bleeding complications are a common and significant concern with the use of currently-available anticoagulants. In recent years, direct oral anticoagulants (DOACs) have emerged as an alternative to warfarin for the prevention and treatment of thromboembolic disease. However, due to the targeted mechanism of action of Direct-Acting Oral Anticoagulants (DOACs), traditional reversal methods such as fresh frozen plasma (FFP) are not thought to significantly influence their reversal.1 Even with the addition of idarucizumab for dabigatran reversal, and 4-factor prothrombin complex concentrate (PCC) for warfarin reversal, there are still numerous questions regarding which patients should be reversed, what is the risk of a thromboembolic event, and how to use these agents, what clinical outcomes are required to assess their efficacy, and what is the optimal intravenous administration duration. The goal of this program is to provide comprehensive updates and strategies for the reversal of oral anticoagulants in order to deliver the best possible care.





At the conclusion of this activity, participants will be able to (or better able to):

  1. Recognize which patients are candidates for reversal and the potential thromboembolic consequences of discontinuing and reversing anticoagulation.
  2. Discuss the evidence to reverse warfarin with Vitamin K, FFP and PCC.
  3. Examine the role and clinical utility of reversal agents for various DOACs.
  4. Explore other reversal agents that are currently in development.



Target Audience


This activity will be designed to inform cardiologists, specialists in internal medicine, hospitalists, surgeons, physician assistants, nurse practitioners, nurses and pharmacists who manage patients undergoing treatment with anticoagulant therapies.



Faculty Disclosure


Dr. Kaatz is a speaker for Janssen, Boehringer Ingelheim, Bristol Myer Squibb/Pfizer, CSL Behring, and Daiichi Sankyo. He is a consultant for Boehringer Ingelheim, Bristol Myer Squibb/Pfizer, Janssen, Daiichi Sankyo and Portola. He has received Research funding from Janssen.

Dr. Hylek is a consultant for Bayer, Bristol Myers Squibb and Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Johnson and Johnson. She also receives grant/research from Bristol Myers Squibb/Pfizer and Johnson and Johnson. She additionally has spoken at symposiums for Bayer, Boehringer Ingelheim and Bristol Myers Squibb/Pfizer.

Ms. Wirth, CNE Course Advisor, is on the speakers bureau for Janssen and she is a consultant for Roche diagnostics.

Dr. Fanola, Course Co-Director, Ms. Patti-Ann Collins, Lead Nurse Planner, Elizabeth Drury, planner, Ms. Elizabeth Goldstein planner, have no relevant financial disclosures.